Treatment of chronic hepatitis C in Asia: When East meets West

@article{Yu2009TreatmentOC,
  title={Treatment of chronic hepatitis C in Asia: When East meets West},
  author={Ming‐Lung Yu and Wan-Long Chuang},
  journal={Journal of Gastroenterology and Hepatology},
  year={2009},
  volume={24}
}
The issue of best treatment for chronic hepatitis C virus (HCV) infection is in constant flux, not only in Western countries but also in Asia. Currently, pegylated-interferon plus ribavirin is the standard of care. Studies from Asia provide evidence to support the same broad treatment strategies for Asian patients as recommended in Western countries. Nevertheless, there is increasing evidence that Asians have a higher likelihood of achieving a sustained virological response (SVR) than their… 

Urgency to treat patients with chronic hepatitis C in Asia

  • J. KaoS. Ahn S. Paik
  • Medicine, Biology
    Journal of gastroenterology and hepatology
  • 2017
TLDR
There is a need to improve current clinical practices for HCV management in Asia, including effective screening, disease awareness, and prevention programs, and to further understand the cost‐effectiveness of IFN‐free regimens.

Similar Treatment Response to Peginterferon and Ribavirin in Asian and Caucasian Patients With Chronic Hepatitis C

TLDR
Comparison of sustained virological response (SVR) rates among Caucasian and Asian-American patients with genotype 1 and 2/3 infection whose HCV genotypes were accurately classified by core sequencing testing found Asian ethnicity to predict SVR rates were not found.

Evolution of Interferon-Based Therapy for Chronic Hepatitis C

TLDR
Clinical factors have been identified as predictors for the efficacy of the IFN-based therapy and Rapid virological response (RVR) is the single best predictor of an SVR to PegIFN-ribavirin therapy.

Study on HCV direct acting drugs in treatment of chronic hepatitis C

TLDR
The development of new models and tools has led to the discovery and clinical development of a large number of new anti­hepatitis C virus (HCV) drugs, and cure rates have increased to more than 90 percent.

Treatment Uptake of Patients with Chronic Hepatitis C: Can We Expect and Do More?

  • C. Dai
  • Medicine
    Digestive Diseases and Sciences
  • 2010
TLDR
The merits of a shortened treatment regimen, which can be attempted without influencing treatment efficacy, include reducing costs of drugs and medical testing as well as improving tolerability for patients, which ensures compliance throughout the course of treatment.

Treatment of Hepatitis C in 2011: What Can We Expect?

  • M. Shiffman
  • Medicine, Biology
    Current gastroenterology reports
  • 2010
TLDR
Direct-acting antiviral agents are currently being developed to treat patients with HCV genotype 1 that will significantly increase rapid virologic response when used with peginterferon and ribavirin, and will yield high rates of SVR with 24 to 28 weeks of treatment.

The Evolution of HCV Treatment in Taiwan

TLDR
The application of IL-28B genetic tests and the insight provided by the viral kinetics might aid in selecting the best candidates for treatment with direct antivirals in the near future in Taiwan.

Virological Responses to Interferon Therapy Combined with Ribavirin with Various HCV Genotypes in Pakistan

TLDR
The heterogeneity ofHCV has great impact on the and specificity of serological and virological assays for the detection of HCV infection.

Host factors determining the efficacy of hepatitis C treatment

TLDR
The treatment of hepatitis C virus infection could be simplified in the near future after pilot studies have demonstrated that potent DAAs might overcome the influence of IL28B polymorphisms.

Linkage of the Hepatitis C Virus Genotype and Interleukin-28 B Genetic Polymorphisms in Asian Patients

TLDR
The findings were in agreement with Montes-Cano and et al.
...

References

SHOWING 1-10 OF 134 REFERENCES

Treatment of Chronic Hepatitis C in Southern Taiwan

TLDR
Long-term follow-up of patients treated with IFN has shown that SVR might reduce the risk of progression to cirrhosis and hepatocellular carcinoma, and some small-scale studies in Taiwan have postulated higher SVR for treatment duration of 12 than of 6 months in patients with genotype 1b.

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.

TLDR
This prospective study showed that virus load, HCV serotype, and IFN dose are important predictors of the virological response to IFN therapy but virus load is the most important factor influencing the efficacy of IFN.

Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection

TLDR
The distribution of HCV‐4 subtypes varies with the geographical origin of transmission and affects the SVR following antiviral treatment, and an overall better response was observed in patients infected with the 4a subtype.

Antiviral treatment of hepatitis C: present status and future prospects

  • K. Koike
  • Medicine, Biology
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • 2006
TLDR
The treatment for HCV infection has progressed significantly, but therapies with new modalities, such as inhibitors of viral protease or RNA polymerase, are still being awaited.

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

TLDR
In this large cohort of chronic hepatitis C patients, SVR was durable up to 18 years after treatment cessation, in addition to fibrosis stability/improvement and cirrhosis regression, which strongly suggests that SVR may be considered to show eradication of HCV infection.

Hepatitis C: natural history, diagnosis, and management.

  • N. Lam
  • Medicine, Biology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1999
TLDR
The virology, epidemiology, clinical spectrum, diagnosis, and management of hepatitis C are reviewed and new agents under development for use against hepatitis C include viral enzyme inhibitors, ribozymes and antisense oligonucleotides, and immunomodulators.

Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C Genotype 4

TLDR
Peginterferon alfa-2b in combination with ribavirin is effective in the treatment of HCV genotype 4 and was well tolerated by most of the patients.

Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C

TLDR
Asians are more likely to achieve an SVR to treatment with peginterferon alfa-2a and ribavirin than whites with chronic hepatitis C, suggesting a genetic influence on the antiviral response.

Higher Rate of Sustained Virologic Response in Chronic Hepatitis C Genotype 6 Treated With 48 Weeks Versus 24 Weeks of Peginterferon Plus Ribavirin

TLDR
Treatment-eligible patients with HCV genotype 6 should be treated with a full course of 48 wk as tolerated, and larger prospective studies are needed to confirm the optimal treatment duration with PEG IFN + RBV.

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

TLDR
The dose effect of interferon-alpha in chronic hepatitis C is confirmed, and six-MU regimen had better efficacy than 3- MU regimen in virologic and histological responses and both regimens had good tolerability and durability in Taiwan.
...